Geron Corporation (GERN)

Currency in USD
1.5700
+0.0600(+3.97%)
Closed·
1.5691-0.0009(-0.06%)
·
Advertisement
GERN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.46001.5900
52 wk Range
1.04002.0100
Key Statistics
Prev. Close
1.51
Open
1.49
Day's Range
1.46-1.59
52 wk Range
1.04-2.01
Volume
11.48M
Average Volume (3m)
11.78M
1-Year Change
12.1429%
Book Value / Share
0.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GERN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.2500
Upside
+170.70%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Geron Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.2500
(+170.70% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy3.00+91.08%4.00Maintain29/01/2026
H.C. Wainwright
Hold---Maintain12/12/2025
H.C. Wainwright
Hold---Maintain09/12/2025
Leerink Partners
Buy2.00+27.39%3.00Maintain05/11/2025

Geron Corporation SWOT Analysis


Rytelo's Rise
Explore Geron's flagship product Rytelo, driving sales growth and exceeding market expectations, positioning the company as a rising star in hematologic malignancies
Leadership Shift
New CEO appointment signals potential strategic changes, aiming to capitalize on Rytelo's success and diversify Geron's product pipeline
Market Expansion
Delve into Geron's growth prospects, including European Union approval for Rytelo and potential new indications, with analysts projecting significant revenue growth
Analyst Outlook
Average price target of $4.00, with "Overweight" ratings reflecting optimism despite challenges. EPS projections show improvement trend from -0.09 to -0.00
Read full SWOT analysis

Geron Corporation Earnings Call Summary for Q2/2026

  • Geron Q2 2026 revenue hit $57.48M, beating estimates by 4.11%; EPS loss of 2 cents missed forecast by 1 cent amid ongoing unprofitability.
  • RYTELO drug sales rose 17% YoY and 11% sequentially, driving revenue growth; company expects FY2026 revenue at mid-to-high end of $220M-$240M range.
  • Operating expenses fell 4% in H1 2026 despite 24% revenue growth, demonstrating improved cost discipline as commercialization strategy gains traction.
  • Shares slipped 0.11% to $1.3385 in premarket trading; company holds $327M in cash and securities with current ratio of 6.78 indicating strong liquidity.
  • Management plans to announce European commercialization strategy by year-end; phase 3 myelofibrosis trial continues on long-term timeline with no changes.
Last Updated: 05/08/2026, 13:46
Read Full Transcript

Earnings

Latest Release
05/08/2026
EPS / Forecast
-0.02 / -0.01
Revenue / Forecast
57.48M / 55.21M
EPS Revisions
Last 90 days

Geron (GERN) Income Statement & Profits

Compare GERN to Peers and Sector

Metrics to compare
GERN
Peers
Sector
Relationship
P/E Ratio
−14.9x−10.4x−0.4x
PEG Ratio
−0.630.240.00
Price/Book
4.6x4.4x2.6x
Price / LTM Sales
4.9x73.8x3.0x
Upside (Analyst Target)
154.8%45.4%47.5%
Fair Value Upside
Unlock−2.8%6.7%Unlock

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
155.34M24.18%243.88M
Other Institutional Investors
471.65M73.41%740.49M
Public Companies & Retail Investors
15.49M2.41%24.31M
Total
642.47M100.00%1.01B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.64%49,115,57177,111
RA Capital Healthcare Fund, L.P.6.66%42,809,75167,211

People Also Watch

0.605
HUMA
+1.51%
4.060
MNKD
+2.53%
175.06
AVY
+1.17%
3.350
GROY
-2.33%
58.450
ETON
-2.42%

FAQ

What Is the Geron (NASDAQ: GERN) Share Price Today?

The Geron stock price today is 1.5700 USD.

What Stock Exchange Does Geron (GERN) Trade On?

Geron is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Geron?

The stock symbol (also called a 'ticker') for Geron is "GERN."

What Is the Current Geron Market Capitalisation?

As of today, Geron (NASDAQ: GERN) market cap is 1.0100B USD.

What Is Geron's (GERN) Earnings Per Share (TTM)?

The Geron EPS is currently -0.1011 (Trailing Twelve Months).

When Is the Next Geron Earnings Date?

Geron's next earnings report will be released on 11/11/2026.

Is GERN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Geron moving averages and other technical indicators, the daily buy/sell signal for GERN stock is Strong Buy.

How Many Times Has Geron Stock Split?

Geron has split 0 times. (See the GERN stock split history page for full effective split date and price information.)

How Many Employees Does Geron Have?

Geron has 258 employees, based on their latest Companies House report.

What is the current trading status of Geron (NASDAQ: GERN)?

As of 07/09/2026, Geron (GERN) is trading at a share price of 1.5700 USD, with a previous close of 1.5100 USD. The stock has fluctuated within a day range of 1.4600 USD to 1.5900 USD, while its 52-week range spans from 1.0400 USD to 2.0100 USD.

What Is Geron (GERN) Price Target According to Analysts?

The average 12-month price target for Geron is 4.2500 USD, with a high estimate of 6 USD and a low estimate of 3 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +170.70% Upside potential.

What Is the GERN After Hours Price?

GERN's last after hours stock price is 1.5691 USD, the stock has decreased by -0.0009, or -0.0600%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.